Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on TVTX. Travere Therapeutics, Inc.’s share was trading at $40.29 as of April 20th. TVTX’s forward P/E was 54.35 , respectively according to Yahoo Finance. Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.  ...